A team of Greek University professors, after 3 decades of research, have developed - with innovative patented technology - a method for producing a fraction of inhibitors of inflammatory and thrombotic factor known as Platelet-Activating Factor (PAF), from by-products of the Mediterranean food industry (oil, winery, fish processing), suitable for a food supplement ingredient with anti-inflammatory and anti-thrombotic action. PAF is implicated in thromboinflammatory - neuroinflammatory diseases and its inhibitors show beneficial effects.
The team has studied in depth the effect of these PAF inhibitors on cardiovascular disease, with in vitro experiments, with cell culture experiments and with in vivo experiments with dietary interventions on experimental animals and humans. This fraction, added in dietary interventions on experimental animals, indicates (directly) that it inhibits the formation of atherosclerotic plaques and regresses (cures) existing atherosclerotic plaques. In cell cultures and humans, its beneficial effect is seen indirectly from its effect on risk factors for cardiovascular disease.
In addition to cardiovascular disease, the literature shows that PAF inhibitors have a beneficial effect on other (thrombo /neuro-) inflammatory diseases (cancer, diabetes, kidney disease, liver disease, allergies, autoimmune diseases, periodontitis, ocular diseases, AIDS and most recently COVID-19).
Due to its natural origin, it is a harmless and and stable substance which can be a dietary supplement in the form of capsules/tablets (alone or with other ingredients) or as an additive in various foods. It should be noted that dietary supplements with PAF inhibitors are not available internationally.
The team proposes a license agreement or a commercial agreement with technical assistance to transfer the rights for producing the above PAF inhibitor fraction as well as for its commercial exploitation worldwide, for a lump sum. Alternatively, the transfer of rights could involve a reduced lump sum plus a percentage of the commercial gains from its exploitation.
